ClinicalTrials.gg
CompletedNCT03129568TICAP-DCMUpdated Nov 26, 2021Results posted

Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy

A Phase 1 interventional study of CDC infusion in Dilated Cardiomyopathy, sponsored by Okayama University. Completed at 1 site in Japan. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by Okayama University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

A phase 1 prospective study to determine the procedural feasibility and safety and preliminary efficacy of intracoronary infusion of cardiosphere-derived cells (CDCs) in patients with dilated cardiomyopathy.

Read the detailed description

Five consecutive patients will be enrolled to a phase 1 study to verify the procedural feasibility and safety with the CDC infusion group.

02

Conditions studied

  • Dilated Cardiomyopathy
03

In context

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

This study's enrollment of 5 is below the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.

Browse Cardiomyopathy, Dilated studies →

Lead sponsor

Okayama University is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as dilated cardiomyopathy.
  • Patients aged under 18 years old.
  • Cardiac \< 40%.

Exclusion criteria

Exclusion Criteria:

  • Contradiction to cardiac magnetic resonance imaging.
  • Cardiogenic shock.
  • A patient with unstoppable extracorporeal circulation.
  • A patient with lethal, uncontrollable arrhythmia.
  • A patient with a complication of coronary artery disease.
  • A patient with a complication of brain dysfunction due to circulatory failure.
  • A patient with malignant neoplasm.
  • A patient with a complication of a serious neurologic disorder.
  • A patient with high-grade pulmonary embolism or pulmonary hypertension.
  • A patient with high-grade renal failure.
  • A patient with multiple organ failure.
  • Active infection (including endocarditis).
  • Sepsis.
  • Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    CDC infusion

    CDCs infusion by coronary intervention.

    Biological: CDC infusion

Interventions

  • BiologicalCDC infusion

    Injection of CDCs (0.3 million per kg of body weight).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.

    Assessment of major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, acute coronary syndrome, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.

    Time frame: 6 months after CDC treatment

Secondary outcomes

  1. Change in Ejection Fraction

    To determine the changes in cardiac function by ejection fraction with cardiac MRI evaluation in CDC-treated participants from baseline to 6 months of follow up.

    Time frame: 6 months after protocol treatment

07

Results

Posted Nov 1, 2021
Limitations and caveats
Single arm study without placebo control comparator

Participant flow

Participant flow — Overall Study
MilestoneCDC Infusion
Started5
Completed5
Not completed0

Outcome measures

PrimaryNumber of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.

Assessment of major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, acute coronary syndrome, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.

Time frame:
6 months after CDC treatment
Reported as:
Count of participants · Participants
Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.
ParticipantsCDC Infusion
Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.1
SecondaryChange in Ejection Fraction

To determine the changes in cardiac function by ejection fraction with cardiac MRI evaluation in CDC-treated participants from baseline to 6 months of follow up.

Time frame:
6 months after protocol treatment
Reported as:
Mean · percentage of ejection fraction
Change in Ejection Fraction
percentage of ejection fractionCDC Infusion
Change in Ejection Fraction4.5 ± 10.2

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CDC Infusion1/5 (20%)1/5 (20%)0/5 (0%)
Most frequent serious events
Most frequent serious events
EventCDC Infusion
heart failureCardiac disorders1/5
infectionRespiratory, thoracic and mediastinal disorders1/5
ischemic eventCardiac disorders1/5

Baseline characteristics

Consecutive enrollment of 5 patients to receive CDC infusion

Age, Continuous
Age, Continuous(years)CDC Infusion
Mean11.4 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)CDC Infusion
Female3
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CDC Infusion
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Cardiac Function
Cardiac Function(percentage of baseline ejection fraction)CDC Infusion
Mean28.5 ± 10.7
08

Study locations

1 site
  • Okayama University Hospital
    Okayama, 700-8558, Japan
09

References and documents

Publications

  • Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res. 2017 Mar 31;120(7):1162-1173. doi: 10.1161/CIRCRESAHA.116.310253. Epub 2017 Jan 4. PubMed 28052915 ↗
  • Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015 Nov;150(5):1198-1207, 1208.e1-2. doi: 10.1016/j.jtcvs.2015.06.076. Epub 2015 Jul 8. PubMed 26232942 ↗
  • Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015 Feb 13;116(4):653-64. doi: 10.1161/CIRCRESAHA.116.304671. Epub 2014 Nov 17. PubMed 25403163 ↗
  • Hirai K, Ousaka D, Fukushima Y, Kondo M, Eitoku T, Shigemitsu Y, Hara M, Baba K, Iwasaki T, Kasahara S, Ohtsuki S, Oh H. Cardiosphere-derived exosomal microRNAs for myocardial repair in pediatric dilated cardiomyopathy. Sci Transl Med. 2020 Dec 9;12(573):eabb3336. doi: 10.1126/scitranslmed.abb3336. PubMed 33298561 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Sep 2018, 17 months.

Results were first posted in Nov 2021, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2017
First posted
Apr 26, 2017
StartActual
Apr 14, 2017
Primary completionActual
Sep 17, 2018
CompletionActual
Dec 9, 2020
Results first posted
Nov 1, 2021
Last update
Nov 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03129568
Lead sponsor
Okayama University
Collaborators
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Responsible party
Hidemasa Oh, MD (Professor, Okayama University) — Principal investigator
First posted
Apr 26, 2017
Start date
Apr 14, 2017
Primary completion
Sep 17, 2018
Completion
Dec 9, 2020
Results posted
Nov 1, 2021
Last update
Nov 26, 2021

Study contacts

Shigeru Uemura, M.D., Ph.D.
study chair · Shonan Tobu Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion